NEW YORK (GenomeWeb) – MDxHealth today announced that Tufts Health Plan will provide its more than 1 million members with access to the firm's ConfirmMDx test for prostate cancer.
The agreement covers Tufts' government and commercial programs and products. Financial and other details were not disclosed.
ConfirmMDx for Prostate Cancer detects the methylation status of biomarkers associated with the cancer development process, identifying patients who many not need a repeat biopsy following a negative result.
In September 2014, the Centers for Medicare & Medicaid Services finalized a conditional coverage policy for reimbursement for the ConfirmMDx prostate cancer test.